Scholarlink

Purpose <p>Concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and fluorouracil (5-FU) (i.e. TPF regimen) has yielded favourable outcomes in treating advanced external auditory canal squamous cell carcinoma (EACSCC). However, safety and efficacy have not been compared across TPF-CCRT and CDDP-based regimens. This study thus aimed to assess the feasibility, safety, and efficacy of TPF-CCRT versus CDDP-CCRT.</p> Methods <p>This retrospective study evaluated 20 patients with T3/T4 EACSCC who underwent CCRT between 2007 and 2023. During radiotherapy, the TPF group (<i>n</i> = 10) received two cycles of 50 mg/m<sup>2</sup> docetaxel and 60 mg/m<sup>2</sup> CDDP on day 1, plus 600 mg/m<sup>2</sup> 5-FU on days 1–4. Meanwhile, the CDDP group (<i>n</i> = 10) received three cycles of CDDP (80 mg/m<sup>2</sup>) triweekly or two cycles of CDDP (60 mg/m<sup>2</sup>) on day 1 and 5-FU (600 mg/m<sup>2</sup>/day) on days 1–4 during RT. Treatment compliance, incidence of adverse events, progression-free survival (PFS), and overall survival (OS) were compared between the groups.</p> Results <p>All patients completed radiotherapy. The incidence of grade ≥ 3 adverse events was not significantly different between the TPF and CDDP groups, but leukopenia (any grade) and alopecia occurred more frequently in the TPF group. Two-year PFS (80% vs. 20%, <i>p</i> &lt; 0.01) and OS rates (100% vs. 40%, <i>p</i> &lt; 0.01) were significantly higher in the TPF group.</p> Conclusion <p>Compared with CDDP-CCRT, TPF-CCRT has excellent feasibility and efficacy and acceptable toxicity for advanced EACSCC, making it a promising treatment option for this malignancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Concurrent chemoradiotherapy with docetaxel, cisplatin, and fluorouracil for patients with advanced external auditory canal squamous cell carcinoma: comparison with cisplatin-based concurrent chemoradiotherapy

  • 期刊论文

  • 发表日期：

    2025年8月31日

查看全文
  • Yushi Ueki,
  • Yuki Ohno,
  • Shusuke Ohshima,
  • Yusuke Yokoyama,
  • Jo Omata,
  • Takeshi Takahashi,
  • Ryusuke Shodo,
  • Kohei Saijo,
  • Kohei Ohtaki,
  • Hiroshi Matsuyama,
  • Riku Aoyama,
  • Manabu Ogi,
  • Nao Takahashi,
  • Arata Horii

摘要

Purpose

Concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and fluorouracil (5-FU) (i.e. TPF regimen) has yielded favourable outcomes in treating advanced external auditory canal squamous cell carcinoma (EACSCC). However, safety and efficacy have not been compared across TPF-CCRT and CDDP-based regimens. This study thus aimed to assess the feasibility, safety, and efficacy of TPF-CCRT versus CDDP-CCRT.

Methods

This retrospective study evaluated 20 patients with T3/T4 EACSCC who underwent CCRT between 2007 and 2023. During radiotherapy, the TPF group (n = 10) received two cycles of 50 mg/m2 docetaxel and 60 mg/m2 CDDP on day 1, plus 600 mg/m2 5-FU on days 1–4. Meanwhile, the CDDP group (n = 10) received three cycles of CDDP (80 mg/m2) triweekly or two cycles of CDDP (60 mg/m2) on day 1 and 5-FU (600 mg/m2/day) on days 1–4 during RT. Treatment compliance, incidence of adverse events, progression-free survival (PFS), and overall survival (OS) were compared between the groups.

Results

All patients completed radiotherapy. The incidence of grade ≥ 3 adverse events was not significantly different between the TPF and CDDP groups, but leukopenia (any grade) and alopecia occurred more frequently in the TPF group. Two-year PFS (80% vs. 20%, p < 0.01) and OS rates (100% vs. 40%, p < 0.01) were significantly higher in the TPF group.

Conclusion

Compared with CDDP-CCRT, TPF-CCRT has excellent feasibility and efficacy and acceptable toxicity for advanced EACSCC, making it a promising treatment option for this malignancy.